This company has been marked as potentially delisted and may not be actively trading. BeiGene (BGNE) Stock Forecast & Price Target Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock Get the Latest News and Ratings for BGNE and Related Stocks Enter your email address to receive the latest news and analysts' ratings for BeiGene and its competitors. Enter your email to sign up for newsletter Sign Up BGNE Analyst Ratings Over TimeTypeCurrent Forecast5/5/24 to 5/5/251 Month Ago4/5/24 to 4/5/253 Months Ago2/5/24 to 2/4/251 Year Ago5/6/23 to 5/5/24Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)Buy5 Buy rating(s)5 Buy rating(s)6 Buy rating(s)8 Buy rating(s)Hold1 Hold rating(s)1 Hold rating(s)2 Hold rating(s)2 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)Consensus Price Target$253.92$253.92$253.69$250.13Forecasted UpsideN/A37.47% Upside37.34% Upside54.16% UpsideConsensus RatingModerate BuyModerate BuyModerate BuyModerate Buy BGNE Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History BGNE Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table BeiGene Stock vs. The CompetitionTypeBeiGeneMedical CompaniesS&P 500Consensus Rating Score 2.83 2.81 2.54Consensus RatingModerate BuyModerate BuyModerate BuyPredicted UpsideN/A3,599.46% Upside17.55% UpsideNews Sentiment RatingNeutral NewsSee Recent BGNE NewsPositive NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails12/3/2024Morgan Stanley3 of 5 stars Reiterated RatingOverweight$300.00+45.81%11/13/2024TD Cowen4 of 5 stars Boost TargetBuy ➝ Buy$254.00 ➝ $260.00+32.21%10/22/2024JPMorgan Chase & Co.2 of 5 stars Boost TargetOverweight ➝ Overweight$200.00 ➝ $235.00+7.12%9/18/2024JMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingR. BenjaminSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMarket Outperform$288.00+45.82%8/8/2024CitigroupSubscribe to MarketBeat All Access for the recommendation accuracy rating Boost TargetBuy ➝ Buy$269.00 ➝ $288.00+57.06%7/9/2024Bank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetNeutral ➝ Neutral$180.00 ➝ $152.50+5.82%3/27/2024Sanford C. BernsteinSubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetMarket Perform ➝ Market Perform$196.00 ➝ $161.00+4.67%2/27/2024GuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetBuy ➝ Buy$350.00 ➝ $345.00+98.62%9/12/2023Royal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy rating Initiated CoverageOutperform$259.00+25.82%9/11/2023MacquarieSubscribe to MarketBeat All Access for the recommendation accuracy rating Initiated CoverageOutperform$259.00+23.78% Get the Latest News and Ratings for BGNE and Related StocksEnter your email address below to receive the latest news and analysts' ratings for BeiGene and its competitors with MarketBeat's FREE daily newsletter. 8/17/2023Jefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy rating Initiated CoverageBuy$287.00+49.22%6/30/202351jobSubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingDowngrade6/30/202322nd Century GroupSubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingDowngrade6/30/20233MSubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingDowngradeAnalyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 03:36 PM ET. Should I Buy BeiGene Stock? BGNE Pros and Cons Explained These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, May 2, 2025. Please send any questions or comments about these BeiGene pros and cons to contact@marketbeat.com. BeiGene Bull Case Here are some ways that investors could benefit from investing in BeiGene, Ltd.: The current stock price is around $191.78, which may present a buying opportunity for investors looking for growth in the biotech sector. Recent short interest has increased, indicating that some investors believe the stock may rise, which can lead to a potential short squeeze and drive the price higher. Institutional ownership is significant, with nearly 49.13% of shares held by institutions, suggesting confidence from large investors in the company's future prospects. BeiGene, Ltd. has shown a strong average daily trading volume, indicating good liquidity and interest in the stock, which can be beneficial for investors looking to enter or exit positions. The company has a solid track record of innovation in the biotech field, which can lead to potential breakthroughs and increased market share in the future. BeiGene Bear Case Investors should be bearish about investing in BeiGene, Ltd. for these reasons: The stock has experienced a decline of about 5.44% over the past year, which may raise concerns about its performance and market competitiveness. There is no float size reported, which can indicate a lack of available shares for trading, potentially leading to volatility in the stock price. Short interest has increased significantly, which may suggest that many investors are betting against the stock, indicating a lack of confidence in its near-term performance. Despite institutional ownership, the overall market sentiment may be cautious due to the competitive nature of the biotech industry, which can impact stock performance. The company has a relatively high days to cover ratio, which means it may take longer for short sellers to cover their positions, potentially leading to increased volatility. BGNE Forecast - Frequently Asked Questions What is BeiGene's forecast for 2025? According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for BeiGene is $253.92, with a high forecast of $300.00 and a low forecast of $152.50. Should I buy or sell BeiGene stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BeiGene in the last twelve months. There is currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BGNE shares. Does BeiGene's stock price have much upside? According to analysts, BeiGene's stock has a predicted upside of ∞ based on their 12-month stock forecasts. Do Wall Street analysts like BeiGene more than its competitors? Analysts like BeiGene more than other "medical" companies. The consensus rating score for BeiGene is 2.83 while the average consensus rating score for "medical" companies is 2.81. Learn more on how BGNE compares to other companies. Stock Forecasts and Research Tools Related Companies Takeda Pharmaceutical Stock Forecast argenx Stock Forecast BioNTech Stock Forecast Beigene Stock Forecast Summit Therapeutics Stock Forecast Teva Pharmaceutical Industries Stock Forecast Intra-Cellular Therapies Stock Forecast Genmab A/S Stock Forecast Dr. Reddy's Laboratories Stock Forecast Moderna Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter This page (NASDAQ:BGNE) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BeiGene, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share BeiGene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BGNE Stock Free BGNE Stock Alerts